GNF-6231 is a potent, orally active and selective Porcupine inhibitor with IC50 of 0.8 nM.

GNE-900 (GNE900) is a potent, selective, ATP-competitive, and orally bioavailable Chk1 inhibitor with IC50 of <1 nM.

GNE-886 is a potent and selective CECR2 bromodomain inhibitor with IC50 of 16 nM.

GNE-6468 (GNE6468) is a potent and selective RORc inverse agonist (EC50=2 nM) with >1,000-fold selectivity for RORc over PPARγ.

GNE-431 is a potent, selective and noncovalent Btk inhibitor with IC50 of 3.2 nM and 2.5 nM for WT Btk and C481S mutant, respectively.

GNE-375 is a potent, selective BRD9 inhibitor with IC50 of 5 nM, displays >480-fold selectivity over BRD4, CECR2, and TAF1.

GNE-371 is a potent and selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and transcription-initiation-factor TFIID subunit 1-like, with an IC50 of 10 nM for TAF1(2).

GNE-3500 (GNE3500) is a potent, selective, and orally bioavailable RORγ inhibitor with IC50 of 47 nM in IL-17 promoter assays.

GNE-293 is a potent and selective PI3Kδ inhibitor with Ki of 0.47 nM, displays 256, 420, 219-fold selectivity over PI3Kα, PI3Kβ, PI3Kγ, respectively.

GNE-2861 is a potent, selective group II PAK (PAK4/5/6) inhibitor with IC50 of 7.5/126/36 nM, respectively, shows selectivity over group I PAKs (IC50=5.42/0.97/>10 uM for PAK1/2/3).

GNE-272 is a in Vivo Probe for the Bromodomains of CBP/EP300.

GNE-220 is a potent and selective inhibitor of MAP4K4 with IC50 of 7 nM, also inhibits MINK (MAP4K6), DMPK and KHS1 (MAP4K5) with IC50 of 9 nM, 476 nM and 1,110 nM.

GNA002 (GNA-002) is a gambogenic acid (GNA) derivative that specifically and covalently binds to Cys668 within the EZH2-SET domain, trigges EZH2 degradation (IC50=1.1 uM) through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination.

GMI-1070 (Rivipansel, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders.

GlyT1 inhibitor 46 is a novel potent, selective, orally available inhibitor of glycine transporter-1 (GlyT1) with IC50 of 38 and 21 nM for rat and human GlyT1, respectively.

Glycopyrronium bromide (CHF 5259) is a peripherally-acting quaternary ammonium antimuscarinic agent with little or no central nervous system activity.

Glycogen is a glycolytic intermediates and high-energy phosphates that can serve as a form of energy storage in humans, animals, fungi, and bacteria.

Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.

Glycodeoxycholate Sodium is a bile salt.

GLPG 0974 is a potent, selective free fatty acid receptor 2 (FFA2, GPR43) antagonist with IC50 of 95 nM.

GLP-1 receptor agonist-1 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

Gln-AMS is an aminoacyl-tRNA synthetases (AARS) inhibitor, which binds the A-domain within the NRPS enzymes.

Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase..

Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase..

GL-1196 is a PAK4 inhibitor that effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclinD1 pathway and CDK4/6 expression.

GK563 (GK-563) is a potent, selective inhibitor of Ca2+-independent phospholipase A2 (GVIA iPLA2) with IC50 of 1 nM, >20,000-fold selectivity over GIVA cPLA2.

GI-530159 (ICA-069771) is a novel potent, selective, mechano-sensitive K2P channel (TERK) opener with EC50 of 1 uM for TERK1.

GHRP-2 is a synthetic hexapeptide Growth Hormone Releasing Peptide (GHRP), which acts on the hypothalamus and the pituitary gland to release growth hormone with a slight stimulator effect on Prolactin, ACTH and Cortisol levels.

GGTI-DU40 is highly selective inhibitor for GGTase-I both in vitro and in living cells. Studies indicate GGTI-DU40 blocks prenylation of a number of geranylgeranylated CaaX proteins. Treatment of MDA-MB-231 breast cancer cells with GGTI-DU40 inhibited thr